LTR Pharma Limited

LTP

LTR Pharma Ltd. operates as a clinical-stage biopharmaceutical company. The company is headquartered in Brisbane, Queensland. The company went IPO on 2023-12-11. The firm is focused on holistically improving men’s health, physically and mentally, through the commercialization of an intranasal spray treatment for Erectile Dysfunction (ED). Its lead product SPONTAN is set apart from existing ED therapies by its mechanism of action-intranasal delivery technology of a PDE5 inhibitor. The nasal cavity is a highly vascular part of the body supporting even and rapid absorption of the drug, empowering it to work in 10 minutes or less. SPONTAN (SDS-089) is a novel intranasal drug (PDE5) delivery platform for Erectile Dysfunction. The firm's subsidiary is LTR Pharma Inc.

Arcadium Lithium PLC

LTM

Arcadium Lithium Plc operates as a lithium chemicals production company. The company is headquartered in Shannon, Clare and currently employs 2,909 full-time employees. The company went IPO on 2023-12-22. The company has various capabilities across lithium extraction processes, including hard-rock mining, conventional brine extraction and direct lithium extraction (DLE), and in lithium chemical manufacturing for high performance applications. The company uses lithium metal to manufacture lithium specialty products, including high purity lithium metal (HPM) and LIOVIX, a printable lithium metal formulation, for primary battery applications and batteries. The company also processes lithium metal into butyllithium, used in the manufacturing of lightweight green tires among other applications, as well as lithium specialty chemicals used in medicine, agriculture, electronics and other industries. The company also offers sustainable process pathways for lithium metal production using various grades of lithium carbonate. The company operates around the world, with facilities and projects in Argentina, Australia, Canada, China, Japan, the United Kingdom and the United States.